Harvard Bioscience (HBIO) announced that its board of directors approved the company’s 1-for-10 reverse stock split of the it’s common stock. The reverse split was approved by the stockholders of the company at a special meeting held on March 6. The reverse split will legally take effect at 4:30 p.m. Eastern Time, on March 13. The reverse split is intended to increase the per share trading price of the company’s common stock to enable the company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HBIO:
- Harvard Bioscience outlines strategy for growth
- Harvard Bioscience reports preliminary Q4 revenue $23.7M
- Harvard Bioscience files to sell 9.5M shares of common stock for holders
- Harvard Bioscience Announces Major Global Manufacturing Consolidation
- Harvard Bioscience closes manufacturing operations in Massachusetts